# Tobacco Cessation – Pediatric/Adult – Inpatient/Ambulatory
## Clinical Practice Guideline

## Table of Contents

- **Executive Summary** ................................................................. 3
- **Scope** .......................................................................................... 5
- **Methodology** .............................................................................. 6
- **Introduction** ................................................................................ 6
- **Recommendations** .................................................................... 7
  1. **Ask About Tobacco Use** .......................................................... 7
  2. **Advise to Quit** ........................................................................ 8
  3. **Assess Willingness to Quit** ......................................................... 8
  4. **Assist in Quit Attempt** ............................................................ 8
     - Patients Willing to Quit .......................................................... 8
     - Patients Not Willing to Quit ...................................................... 14
  5. **Arrange Follow-up (Prevent Relapse)** ..................................... 16
  6. **Considerations for Specific Populations** ................................ 17
     - Adolescents and Children ....................................................... 17
     - Other Tobacco and Nicotine Users .......................................... 18
     - Hospitalized Tobacco Users .................................................... 18
     - Pregnant Women ..................................................................... 18

- **UW Health Implementation** ..................................................... 19
- **References** .................................................................................. 19

**Note: Active Table of Contents -- Click to follow link**
CPG Contacts for Content:
Name: Douglas Jorenby, PhD – Internal Medicine, UW-CTRI Clinical Services Director
Phone Number: (608) 262-8673
Email Address: dej@medicine.wisc.edu

Name: Robert Adsit, M.Ed – UW-CTRI Outreach Director
Phone Number: (608) 262-7557
Email Address: ra1@ctri.medicine.wisc.edu

CPG Contact for Changes:
Name: Lindsey Spencer, MS – Center for Clinical Knowledge Management (CCKM)
Phone Number: (608) 890-6403
Email Address: lspencer2@uwhealth.org

Coordinating Team Members:
Richard L. Brown, MD, MPH – Family Medicine
Brittany Allen, MD – Pediatrics (Adolescent Medicine)
Paula Cody, MD – Pediatrics (Adolescent Medicine)
Amy Skora, BS, CHES – UW-CTRI Outreach Specialist for Southern Wisconsin
Christina Lightbourn, MS, CSAC – UW Northeast Family Medical Center Health Ed.
Cindy Gaston, PharmD – Drug Policy Program
Nikki Nellen, BSN, RN – Physicians Plus Insurance Corporation (PPIC)
Robin Perry, CHES – Unity Health Insurance
Jen Grice, PharmD – Center for Clinical Knowledge Management (CCKM)

Review Individuals/Bodies:
Michael Fiore, MD, MPH, MBA – Internal Medicine, UW-CTRI Director
Alex Young, MD – Family Medicine
James Stein, MD – Cardiovascular Medicine (Preventive Cardiology)
Karen Allaire, RN, MS, AHN-BC, CPNP-BC – AFCH Learning Center

Committee Approvals/Dates:
Clinical Knowledge Management (CKM) Council (August 28, 2014)

Release Date: August 2014

Next Review Date: August 2016
Executive Summary

Guideline Overview
This guideline is based primarily on the 2008 Department of Health and Human Services guidelines for Treating Tobacco Use and Dependence\(^1\), with support provided by the 2009 and 2013 U.S. Preventive Services Task Force recommendations\(^2,3\) and the American Academy of Pediatrics Policy Statement\(^4\) (reaffirmed in 2014). Inpatient recommendations are derived from the 2008 Department of Health and Human Services guidelines as well as the 2012 Wisconsin Hospital Association(WHA)/University of Wisconsin Center for Tobacco Research & Intervention (UW-CTRI) guideline.\(^5\)

Key Practice Recommendations
1. Ask every patient on admission or during each clinic visit if he or she uses tobacco and document tobacco use status in the patient’s medical record.
2. Advise every patient who uses tobacco to stop.
3. Assess the patient’s willingness to make a quit attempt.
4. Assist patients with quitting by providing evidence-based counseling and medication and develop a tobacco abstinence plan.
5. Assist patients with managing withdrawal symptoms, especially during hospitalization by providing counseling and medication.
6. Arrange for follow-up to assess smoking status and provide supportive contact.

Companion Documents
1. Tobacco Cessation Algorithm
2. Tobacco Dependence Treatment Inpatient Flowchart

Related UW Health Clinical Practice Guidelines
1. UW Health Standard Rooming Criteria – Pediatric/Adult – Ambulatory Guideline
2. UW Health Preventive Health Care – Pediatric/Adult – Ambulatory Guideline
3. UW Health Hypertension – Adult – Inpatient/Ambulatory Guideline
4. UW Health Myocardial Infarction – Adult – Inpatient Guideline
5. UW Health Ventricular Assist Device – Adult – Inpatient/Ambulatory Guideline
6. Standards of Medical Care in Diabetes – Pediatric/Adult – Inpatient/Ambulatory Guideline
7. UW Health Asthma – Pediatric/Adult – Inpatient/Ambulatory Guideline
8. UW Health Chronic Obstructive Pulmonary Disease – Adult – Inpatient/Ambulatory Guideline

External Resources
1. UW Center for Tobacco Research and Intervention (UW-CTRI)
2. Wisconsin Tobacco Quit Line
   a. 1-800-QUIT NOW (763-8669) (English) or 1-877-266-3863 (Spanish)
   b. 1-800-483-3114 (Fax to Quit)
3. UW Center for Tobacco Research and Intervention (UW-CTRI) Inpatient Guideline
4. First Breath Training Program (for pregnant women)
5. UW Center for Tobacco Research and Intervention (UW-CTRI) Billing Codes
Pertinent UW Health Policies & Procedures
1. UWMF Policy- Smoke and Tobacco Free Policy
2. UWMF Policy- Patient Medical Record
3. UWHC Policy 1.41- Smoke Free/Tobacco Free Workplace
4. UWHC Policy 8.47- Screening, Assessment and Reassessment of Patients
5. UWHC Policy 8.02- Assessment and Reassessment of Patients and Documentation in Clinics

Patient Resources:
1. Healthwise: Smokeless Tobacco: Quitting
2. Healthwise: Anti-Smoking Medication: Deciding About
3. Healthwise: Smoking: Stopping
4. Healthwise: Teens Thinking About Quitting Smoking: After Your Visit
5. Health Facts For You #3096: Quit Smoking (English)
6. Health Facts For You #6763: Quit Smoking (Spanish)
7. Health Facts For You #2022: Quit Smoking Fact Sheet
8. Health Facts For You #7515: Why You Should Quit Smoking
9. Health Facts For You #7008: Tobacco Use- How to Avoid Once You’ve Quit
10. Health Facts For You #6141: Using a Nicotine Patch
11. Health Facts For You #6150: Smoking and Wound Healing (Burn Patients)
12. Health Facts For You #5328: Bupropion ER (ZYBAN®) for Smoking Cessation

External Resources for Patients
1. UW-Center for Tobacco Research and Intervention (UW-CTRI) Fact Sheets
   a. Plan to Quit
   b. Quit Chewing Tobacco Fact Sheet
   c. Electronic Cigarettes (E-cigs) Fact Sheet
2. UW-Center for Tobacco Research and Intervention (UW-CTRI) Smoker Website
3. First Breath Training Program Website (for pregnant women)
Scope

Disease/Condition(s):
Tobacco Use, Smoking

Clinical Specialty:
Inpatient Units, Primary Care, Specialty Clinics

Intended Users:
Physicians, Primary Care Physicians, Physician Assistants, Hospitalists, Nurse Practitioners, Advanced Practice Nurses, Registered Nurses, Medical Assistants, Pharmacists

CPG objective(s):
To assist clinicians by providing a framework for the evaluation and treatment of adolescent and adult tobacco users.

Target Population:
Children, adolescent (11-17 years) and adult patients who use or are exposed to tobacco/nicotine products.

Interventions and Practices Considered:
1. Screen for tobacco use
2. Advise to quit and assess willingness to quit
3. Assist in quit attempt via counseling, motivational intervention, or pharmacotherapy
4. Arrange follow-up to prevent relapse

Major Outcomes Considered:
Tobacco use cessation, quit rates

Guideline Metrics:
Joint Commission Reporting Requirements:
1. Proportion of hospitalized inpatients 18 yrs. or over who are screened for tobacco use
2. Tobacco use treatment provided or offered during hospital stay
3. Tobacco use treatment during hospital stay
4. Tobacco use treatment provided or offered at discharge
5. Tobacco use treatment at discharge
6. Tobacco use assessment after discharge (30-day follow-up)
Methodology

Methods Used to Collect/Select the Evidence: The steps used to develop this report include: (1) completing a comprehensive search of the literature; (2) conducting an in-depth review of relevant abstracts and articles; (3) preparing evidence tables to assess the weight of current evidence with respect to past recommendations and new and unresolved issues; (4) conducting thoughtful discussion and interpretation of findings; (5) ranking strength of evidence underlying the current recommendations that are made; (6) updating text, tables, figures, and references of the existing guidelines with new findings from the evidence review.

Methods Used to Assess the Quality and Strength of the Evidence: Comprehensive review of over 8,700 articles in the peer-reviewed literature from 1975 to 2008 conducted by the U.S. Public Health Service (PHS) Clinical Practice Guideline Panel. Published, peer-reviewed, randomized controlled trials were read and rated independently by at least three reviewers. Evidence collected since the 2008 PHS review (2008-2014) was evaluated by the guideline workgroup.

Rating Scheme for the Strength of the Evidence and Recommendations:
Each recommendation and its strength of evidence reflects consensus of the PHS Guideline Panel and/or of the UW Health workgroup members. The following rating scheme developed within the PHS Guideline was applied to this guideline:

<table>
<thead>
<tr>
<th>Rating</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Multiple well-designed randomized clinical trials, directly relevant to the recommendation, yielded a consistent pattern of findings.</td>
</tr>
<tr>
<td>B</td>
<td>Some evidence from randomized clinical trials supported the recommendation, but the scientific support was not optimal.</td>
</tr>
<tr>
<td>C</td>
<td>Reserved for important clinical situations in which the Panel achieved consensus on the recommendation in the absence of relevant randomized clinical trials.</td>
</tr>
</tbody>
</table>

Methods Used to Formulate the Recommendations: Review of current literature and consensus agreement among workgroup members.

Introduction
Forty-two million American adults and about three million middle and high school student smoke. On average, compared to people who have never smoked, smokers suffer more health problems and disability due to their smoking. Smoking causes 87% of lung cancer deaths, 32% of coronary heart disease deaths, and 79% of all cases of chronic obstructive pulmonary disease (COPD). It is estimated that the economic cost attributed to smoking and exposure to tobacco smoke is $300 billion annually, with direct medical costs of at least $130 billion and productivity losses of more than $150 billion per year.6
Recommendations
See Tobacco Cessation Algorithms in Appendix A and Appendix B.

1. Ask About Tobacco Use
Assessment of tobacco use is the first critical step in decreasing tobacco use. Assessment success is enhanced if:

- Screening guidelines are used at each clinic site.
- A system such as an electronic medical record prompt of vital sign stamp is used to indicate status.
- The person taking the other vital signs performs the assessment.

Every patient should be assessed for tobacco use and/or secondhand smoke exposure at every clinical visit, whether inpatient or outpatient, when vital signs are obtained or during every inpatient hospitalization.1,4,5,7 (Grade A)

Refer to Table 1 below for screening questions based upon patient age or patient scenario. As parental smoking and tobacco use are two of the strongest risk factor for smoking initiation in children, assess smoking status of the parent or guardian during pediatric visits.3,8 (Grade B)

Non-use should be reinforced by providers and other health care professionals, especially among former tobacco users.1 (Grade C)

<table>
<thead>
<tr>
<th>Table 1. Suggested Screening Question(s) Based Upon Patient Age/Scenario (Grade C)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Single Screening Question (Adults 18 years or older)</strong></td>
</tr>
<tr>
<td>How often have you used tobacco within the last month?</td>
</tr>
<tr>
<td><strong>Screening Questions (Adolescents 11-17 years)</strong></td>
</tr>
<tr>
<td>During the past 12 months, have you used tobacco or nicotine products (i.e. E-cigarettes)?</td>
</tr>
<tr>
<td><strong>Screening Question (Pregnant Adults)1</strong></td>
</tr>
</tbody>
</table>
| Which of the following statements best describes your cigarette smoking?  
  a) I smoke regularly now; about the same as before finding out I was pregnant.  
  b) I smoke regularly now, but I’ve cut down since I found out I was pregnant.  
  c) I smoke every once in a while.  
  d) I have quit smoking since finding out I was pregnant.  
  e) I wasn’t smoking around the time I found out I was pregnant, and I don’t currently smoke cigarettes. |
2. Advise to Quit

In a clear, strong, and personalized manner, urge every tobacco user to quit.\(^1\) (Grade A)

Evidence shows that physician advice to quit smoking increase abstinence rates. Advice should be:

- **Clear**—“It is important that you quit smoking (or using chewing tobacco) now, and I can help you.” “Cutting down while you are ill is not enough.” “Occasional or light smoking is still dangerous.”
- **Strong**—“As your clinician, I need you to know that quitting smoking is the most important thing you can do to protect your health now and in the future. The clinic staff and I will help you.”
- **Personalized**—Tie tobacco use to current symptoms and health concerns, and/or its social and economic costs, and/or the impact of tobacco use on children and others in the household. “Continuing to smoke makes your asthma worse, and quitting may dramatically improve your health.” “Quitting smoking may reduce the number of ear infections your child has”.

3. Assess Willingness to Quit

Assess every tobacco user’s willingness to make a quit attempt at the current time.\(^1\) (Grade A)

4. Assist in Quit Attempt

Minimal interventions lasting less than 3 minutes increase overall tobacco abstinence rates. Every tobacco user should be offered at least minimal intervention, whether or not the patient is referred to an intensive intervention.\(^1,9\) (Grade A)

**Patients Willing to Quit**

For the patient willing to make a quit attempt, offer medication and provide or refer for counseling or additional treatment to help the patient quit smoking.\(^1\) (Grade A)

**Counseling**

Counseling provided by many different types of providers and other staff (physicians, nurses, dentists, psychologists, pharmacists, etc.) as well as in different formats (practical counseling/problem-solving treatment or support/encouragement) is effective in increasing tobacco cessation rates.\(^1,10\) (Grade B)

Both individual and group counseling are effective and are more effective than no counseling. While the choice of format will depend on the provider and patient, a strong dose-response relationship exists between counseling intensity and cessation success.\(^1\) (Grade A) Person- to-person treatment delivered for four or more sessions appears especially effective in increasing abstinence rates. Whenever feasible, physicians should strive to meet four or more times with patients who are attempting to quit tobacco use.\(^1\) (Grade A)
**Problem-solving Treatment Component**

| Recognition of danger situations – Identification of events, internal states, or activities that are thought to increase the risk of smoking or relapse | Being around other smokers  
Being under time pressure  
Getting into an argument  
Experiencing urges or negative moods  
Drinking alcohol |
|---|---|
| Coping skills -- Identification and practice of coping or problem-solving skills. Typically, these skills are intended to cope with danger situations. | Learning to anticipate and avoid danger situations  
Learning cognitive strategies that will reduce negative moods  
Accomplishing lifestyle changes that reduce stress, improve quality of life, or produce pleasure  
Learning cognitive and behavioral activities that distract attention from smoking urges |
| Basic information -- Provision of basic information about smoking and successful quitting. | The nature/time course of withdrawal  
The addictive nature of smoking  
The fact that smoking (even a single puff) increases the likelihood of full relapse |

During the counseling sessions, it is important to assist the patient is developing a quit plan. Conversations surrounding quit plans should contain the following information:  
- Set a quit date (ideally within 2-3 weeks)  
- Tell others and ask for support (i.e., alert coworkers, family, friends)  
- Anticipate and plan for challenges and temptations (including withdrawal symptoms).  
- Remove all tobacco products from home, car, and work environments.  
- Stress total abstinence and sticking with treatment even if there is a slip or lapse.

To provide more intensive counseling and support to patients, the following options are also available:  
- Center for Tobacco Research and Intervention for individual or group tobacco cessation counseling.  
- Quit Lines – 1-800-QUIT-NOW (800-784-8669); in Spanish 1-877-266-3863. Counselors are available 24/7.  
- Fax to Quit – 1-800-483-3114 (attachment: sample consent form). This program links the services of the Wisconsin Tobacco Quit Line directly to the potential quitter with the help of health care providers.

With Fax to Quit, tobacco users no longer have to take the first step of calling the Quit Line. Instead, a quit coach proactively contacts the tobacco user to provide an intervention after receiving a faxed consent form. The Quit Line faxes a report back to the health care provider when the contact is made with the potential quitter.
Please contact a Center for Tobacco Research and Intervention (CTRI) Regional Outreach Specialist (ROS) for more information.

**Pharmacotherapy**

The efficacy of tobacco-cessation counseling interventions is enhanced by the use of pharmacologic therapy. Pharmacologic support is recommended to all smokers who are motivated to make a quit attempt, in the absence of specific contraindications (i.e., pregnant women, smokeless tobacco users, light smokers and adolescents; light smokers are defined as anyone who smokes fewer than 10 cigarettes per day). Nicotine replacement therapy (NRT) may also be used in conjunction with physician encouragement and instruction to reduce daily smoking as much as possible in patients unwilling to quit. Additionally, pharmacotherapy may be used to minimize withdrawal symptoms in hospitalized patients who are unwilling to make a quit attempt. (Grade A)

Pharmacologic support will be most successful when one or more of the following criteria are met:

- The patient is motivated to quit within the month.
- The patient agrees to quit using tobacco products with the start if nicotine replacement therapy (or 1-2 weeks after the start of bupropion or Varenicline).
- The patient agrees to participate in a follow-up program.
- Previous quit attempts have failed because of withdrawal symptoms

Information on the contraindications, adverse effects, and recommended doses for FDA-approved medications is listed in Table 2.

**Precautions in patient using non-nicotine pharmacotherapy**

The U.S. FDA added new Boxed Warnings for the two non-nicotine smoking cessation pharmacotherapies, bupropion (Zyban™ and generics) and varenicline (Chantix™), highlighting the risk of serious neuropsychiatric symptoms. The boxed warning for these pharmacotherapies directs clinicians to monitor patients for the emergence of such symptoms, and if they emerge, to continue monitoring until they resolve.

**Pregnancy and lactation**

Pregnant smokers should be encouraged to quit without medication. The nicotine patch has not been shown to be effective for treating tobacco dependence in pregnant smokers. (The nicotine patch is an FDA pregnancy Class D agent.) The nicotine patch has not been evaluated in breastfeeding patients, however nicotine and its metabolites are present in human milk and therefore use is discouraged.

**Cardiovascular diseases**

Nicotine replacement therapy (NRT) is not an independent risk factor for acute myocardial events. NRT should be used with caution among particular cardiovascular patient groups: those in the immediate (within 2 weeks) post myocardial infarction period, those with serious arrhythmias, and those with unstable angina pectoris.
Skin reactions
Up to 50% of patients using the nicotine patch will have a mild and self-limiting local skin reaction that can worsen over the course of therapy. Hydrocortisone (5%) or triamcinolone (0.5%) and patch rotation may reduce local reactions. Less than 5% of patients require discontinuation of patch treatment.

Adolescents/Children
No medications are currently approved by the U.S. Food and Drug Administration for tobacco cessation in children and adolescents. Although nicotine replacement has been shown to be safe in adolescents, there is little evidence that these medications and bupropion SR are effective in promoting long-term smoking abstinence among adolescent smokers. As a result, they are not recommended as a component of pediatric tobacco use interventions.

The amounts of nicotine that are tolerated by adult smokers can produce symptoms of poisoning and be potentially fatal to children. Used and unused nicotine delivery systems should be kept out of the reach of children and pets.
<table>
<thead>
<tr>
<th>Medication</th>
<th>Contraindications/Precautions</th>
<th>Adverse Effects</th>
<th>Dosage</th>
<th>Initiation &amp; Use</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bupropion SR 150</strong></td>
<td>Not for use in patients:</td>
<td>- Insomnia</td>
<td>Days 1-3: 150 mg each morning &lt;br&gt;Days 4-end: 150 mg twice daily (at least 8 hours apart)</td>
<td>Start 1-2 weeks before quit date; use 2-6 months</td>
</tr>
<tr>
<td>(Generic, Zyban, Wellbutrin SR)</td>
<td>- Use monoamine oxidase (MAO) inhibitor &lt;br&gt;- Use of bupropion in any other form &lt;br&gt;- History of seizures or risk for seizures &lt;br&gt;- History of eating disorders &lt;br&gt;FDA Boxed Warning</td>
<td>- Dry mouth</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nicotine Gum</strong></td>
<td>- Caution with dentures &lt;br&gt;- Can worsen dental problems &lt;br&gt;- Do not eat or drink 15 minutes before or during use</td>
<td>- Mouth soreness &lt;br&gt;- Stomach ache</td>
<td>If smoking &gt; 30 min. after waking: 2 mg &lt;br&gt;If smoking &lt; 30 min. after waking: 4 mg (Grade B)</td>
<td>1 piece every 1-2 hrs. (6-15 pieces/day) for the first 6 weeks, every 2-4 hours for the next 3 weeks, every 4-8 hours for the final 2 weeks; use for 3 months</td>
</tr>
<tr>
<td>(Generic, Nicorette)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nicotine Inhaler</strong></td>
<td>- May irritate mouth/throat at first (improves with use) &lt;br&gt;- Use with caution in patients with bronchospastic disease</td>
<td>- Local irritation of mouth &amp; throat</td>
<td>6-16 cartridges/day &lt;br&gt;Inhale 80 times/cartridge &lt;br&gt;May save partially-used cartridge for next day</td>
<td>Pre-quit: Up to 6 months before quit date &lt;br&gt;Post-quit: Up to 6 months; taper at end</td>
</tr>
<tr>
<td>(Nicotrol inhaler)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nicotine Lozenge</strong></td>
<td>- Do not eat or drink 15 minutes before or during use &lt;br&gt;- One lozenge at a time &lt;br&gt;- Limit 20 in 24 hrs.</td>
<td>- Hiccups &lt;br&gt;- Cough &lt;br&gt;- Heartburn</td>
<td>If smoke &gt; 30 min. after waking: 2 mg &lt;br&gt;If smoking &lt; 30 min. after waking: 4 mg &lt;br&gt;Maximum dose is 20 lozenges/day</td>
<td>Use 3-6 months &lt;br&gt;Weeks 1-6: 1 every 1-2 hrs. &lt;br&gt;Weeks 7-9: 1 every 2-4 hrs. &lt;br&gt;Weeks 10-12: 1 every 4-8 hrs.</td>
</tr>
<tr>
<td>(Grade B)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Generic, Commit)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medication</td>
<td>Contraindications/Precautions</td>
<td>Adverse Effects</td>
<td>Dosage</td>
<td>Initiation &amp; Use</td>
</tr>
<tr>
<td>------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td>-------------------------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Nicotine Nasal Spray (Nicotrol NS) | - Do not use in patients with severe reactive airway disease  
- Avoid use in patients with chronic allergic rhinitis, nasal polyps, or sinusitis  
- May irritate nose (improves with use)  
- May cause dependence                        | - Nasal irritation  
- Local skin reaction  
- Insomnia                                      | 0.5 mg/spray  
1 "dose" = 1 spray per nostril  
1-2 doses/hour  
8-40 doses/day                      | Use 3-6 months; taper at end  
DO NOT inhale                                                                                   |
| Nicotine Patch (Generic, Nicoderm CQ, Nicotrol) | - Do not use in patients with severe eczema or psoriasis                                        | - Local skin reaction  
- Insomnia                                      | One patch per day  
If > 10 cigarettes/day: 21 mg  
for 4 weeks, 14 g for 2-4 weeks  
7 mg for 2-4 weeks                      | Pre-quit: Up to 6 months prior to quit date  
Post-quit: 12 weeks                                                                   |
| Varenicline (Chantix)              | Use with cause in patients:  
- With significant renal impairment  
- With serious psychiatric illness  
**FDA Boxed Warning**                                                                                       | - Nausea  
- Insomnia  
- Abnormal, strange dreams                        | Days 1-3: 0.5 mg every morning  
Days 4-7: 0.5 mg twice daily  
Days 8-end: 1 mg twice daily                     | Start 1 week before quite date and use 3-6 months OR  
Begin and then quit between day 8 and 36. |
| Combination Therapy: Patch + short-acting nicotine products | Only patch + bupropion is currently FDA-approved  
Follow instructions for individual medications                                                   | See above.                                 | See above.                                                                                   | See above.                                              |
Patients Not Willing to Quit

For patients unwilling to quit, provide motivational interventions designed to increase future quit attempts.\(^1\) (Grade B) Motivational intervention may include counseling strategies such as motivational interviewing\(^23-26\) or discussions which identify or touch on content related to the “5 Rs” (relevance, risks, rewards, roadblocks, and repetition).\(^25,27,28\) Motivational intervention does support an increase in quit attempts in individuals not already willing to quit.\(^25,29,30\)

Understanding what motivates patients to want to quit is critical to understanding why a patient succeeds or fails. Emphasize the importance of learning from prior quit attempts in achieving success. Reinforce the role of social supports such as spouse, children, and grandchildren. A patient unwilling to quit may respond to motivational interventions following the “5 Rs” (Table 3), especially when physician time or training does not permit motivational interviewing.\(^1,10\) (Grade A)

Table 3. The "5 Rs" of Motivational Intervention

<table>
<thead>
<tr>
<th>Relevance</th>
<th>Encourage the patient to indicate why quitting is personally relevant, being as specific as possible. Motivational information has the greatest impact if it is relevant to a patient’s disease status or risk, family or social situation (e.g., having children in the home), health concerns, age, gender, and other important patient characteristics (e.g., prior quitting experience, personal barriers to cessation).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk</td>
<td>Ask the patient to identify the potential negative consequences of tobacco use and highlight those that seem most relevant to the patient. Examples of consequences include:</td>
</tr>
<tr>
<td></td>
<td>• Acute risks: shortness of breath, exacerbation of asthma, impotence, infertility, increased risk of respiratory infections, harm to pregnancy</td>
</tr>
<tr>
<td></td>
<td>• Long-term risks: heart attacks, strokes, lung and other cancers, COPD (chronic bronchitis and emphysema), osteoporosis, long-term disability, the need for extended care.</td>
</tr>
<tr>
<td></td>
<td>• Environmental risks: increased risk of lung cancer and heart disease in spouse, increased risk for low birth-weight, sudden infant death syndrome (SIDS), middle ear diseases, and respiratory infections in children of smokers.</td>
</tr>
<tr>
<td>Reward</td>
<td>Ask the patient to identify the potential benefits of quitting tobacco use; highlight those that seem most relevant to the patient. Examples of rewards include:</td>
</tr>
<tr>
<td></td>
<td>• Food will taste better</td>
</tr>
<tr>
<td></td>
<td>• Save money</td>
</tr>
<tr>
<td></td>
<td>• Home, car, breath will smell better</td>
</tr>
<tr>
<td></td>
<td>• Have healthy babies and children</td>
</tr>
<tr>
<td></td>
<td>• Perform better in physical activities</td>
</tr>
<tr>
<td></td>
<td>• Improved sense of smell</td>
</tr>
<tr>
<td></td>
<td>• Feel better about yourself</td>
</tr>
<tr>
<td></td>
<td>• Improved health</td>
</tr>
<tr>
<td></td>
<td>• Feel better physically</td>
</tr>
<tr>
<td></td>
<td>• Setting a good example for children and decreasing the likelihood they will smoke</td>
</tr>
</tbody>
</table>
Ask the patient to identify barriers to quitting and note elements of treatment (problem solving, pharmacotherapy) that could address the barriers. Common barriers include:

- Withdrawal symptoms
- Fear of failure
- Weight gain
- Lack of support
- Depression
- Enjoyment of tobacco
- Being around tobacco users
- Limited knowledge of effective treatment options

The motivational intervention should be repeated every time an unmotivated patient visits the clinic setting. Tobacco users who have failed in previous quit attempts should be told that most people make repeated quit attempts before they are successful.

Motivational interviewing is a specialized technique which requires intensive training, as well as ongoing practice. This counseling strategy is based upon four general principles: expressing empathy, identifying discrepancy, rolling with resistance, and supporting patient self-efficacy (Table 4).

| Express Empathy | Use open-ended questions to explore:  
|                 | - The importance to addressing smoking or other tobacco use (e.g., “How important do you think it is for you to quit smoking?”).  
|                 | - Concerns and benefits of quitting (e.g., “What might happen if you quit?”).  
|                 | Use reflective listening to seek shared understanding:  
|                 | - Reflect words or meaning (e.g., “So you think smoking helps you to maintain weight.”).  
|                 | - Summarize (e.g., “What I have heard so far is that smoking is something you enjoy. On the other hand, your boyfriend hates your smoking, and you are worried you might develop a serious disease.”).  
|                 | Normalize feelings and concerns (e.g., “Many people worry about managing without cigarettes.”).  
|                 | Support the patient’s autonomy and right to choose or reject change (e.g., “I hear you saying you are not ready to quit smoking right now. I’m here to help you when you are ready.”). |

| Develop Discrepancy | Highlight the discrepancy between the patient’s present behavior and expressed priorities, values and goals (e.g., “It sounds like you are very devotes to your family. How do you think your smoking is affecting your children?”).  
|                    | Reinforce and support “change talk” and “commitment” language (e.g., “So, you realize how smoking is affecting your breathing and making it hard to keep up with your kids;” and “It’s great that you are going to quit when you get through this busy time at work.”).  
|                    | Build and deepen commitment to change (e.g., “There are effective treatments that will ease the pain of quitting, including counseling and many medication options;” and “We would like to help you avoid a stroke like the one your father had.”) |

| Roll with Resistance | Back off and use reflection when the patient expresses resistance (e.g., “Sounds like you are feeling pressured about your smoking.”).  
|                      | Express empathy (e.g., “You are worried about how you would manage withdrawal symptoms.”).  
|                      | Ask permission to provide information (e.g., “Would you like to hear about some strategies that can help you address that concern when you’re ready to quit?”). |

Table 4. Motivational interviewing principles
Support Self-Efficacy

- Help the patient to identify and build on past successes (e.g., "so you were fairly successful the last time you tried to quit?").
- Offer options for achievable small steps toward change:
  - Call the Quit Line (1-800 QUIT-NOW) for advice and information.
  - Read about quitting benefits and strategies.
  - Change smoking patterns (e.g., no smoking in the home).
  - Ask the patient to share his or her ideas about quitting strategies.

5. Arrange Follow-up (Prevent Relapse)

For the patient willing to make a quit attempt, arrange for follow-up contacts, beginning within the first week after the quit date or discharge. Follow-up contacts may include a scheduled cessation counseling session with the attending physician, a follow-up telephone call by designated hospital staff, referral to group, community, or health plan cessation counseling (i.e., UW-CTRI), or education and information regarding quit lines (1-800-QUIT NOW). Insufficient evidence exists to support the use of any specific behavioral intervention which would help recent quitters avoid relapse.

For patients unwilling to make a quit attempt at the time, address tobacco dependence and willingness to quit at the next clinic visit. (Grade B)

All quitters are at risk of relapse but several groups of patients are at higher risk of relapse and should have more intensive phone or office visit follow up. Predictors of relapse include:
- High levels of nicotine dependence
- Psychiatric comorbidity
- Low levels of motivation to quit
- Post-partum

Every ex-tobacco user undergoing relapse prevention should receive congratulations, encouragement, and a request from the provider that they remain abstinent. (Grade C) When encouraging a recent quitter, a provider may use open-ended questions to identify any success or barriers the patient is experiencing. These may include:

Successes:
- The benefits, including health benefits, which the patient may derive from cessation.
- Any success the patient has had in quitting (duration of abstinence, reduction on withdrawal).

Disadvantages or Barriers to Abstinence:
- Anticipated problems or threats to maintaining abstinence.
- Weight gain – the clinician might make dietary, exercise, or lifestyle recommendations, or might refer the patient to a specialist or program. The patient can be reassured that some weight gain after quitting is common, is usually temporary, and that significant dietary restrictions soon after quitting may be counterproductive.
• Negative mood or depression – if significant, the clinician might prescribe appropriate medications or refer the patient to a specialist.
• Prolonged withdrawal symptoms – if the patient reports prolonged craving or other withdrawal symptoms, the clinician might consider extending therapy.
• Lack of support for cessation – the clinician might schedule follow-up phone calls with the patient, help the patient identify sources of support within his/her environment, or refer the patient to an appropriate organization that offers cessation counseling or support.

6. Considerations for Specific Populations

Adolescents and Children
The U.S. Preventive Services Task Force (USPSTF) recommends that clinicians provide interventions, including education and brief counseling, to prevent initiation of tobacco use in school-aged children and adolescents.\(^3,4\) (Grade B) While screening for personal tobacco use should begin at age 11, anticipatory guidance and education may be appropriate at a much earlier age. The American Academy of Pediatrics (AAP) supports beginning anticipatory guidance at the age of 5 years.\(^4\) Children and adolescents should be warned about the harmful effects of tobacco and the ease with which experimentation progresses to addiction and regular use.\(^4,7\)

Counseling has been shown to be effective in adolescents, therefore adolescents who smoke should be provided counseling interventions which aid them in quitting smoking.\(^1,3,4\) (Grade B) The literature varies on counseling method (i.e., intensity, content, format), however providers may use motivational interventions which are adapted for the adolescent population.\(^3,5\) The interventions should contain content related to enhancing motivation, establishing rapport, goal setting, promotion of problem-solving and skills training, as well as relapse prevention.\(^1,2,5,6,36,37\)

Here are a number of brief messages or talking points which may be used when talking to teenage patients:
• Tobacco causes yellow teeth and fingers, bad breath, smelly clothes, and wrinkled skin.
• Cigarettes contain 4000 chemicals, 400 are toxic (arsenic & formaldehyde), and 40 cause cancer.
• Eating healthy foods and exercising is a better way to lose weight than smoking.
• Smoking a pack a day costs more than $200 per month – more than the cost of an X-Box game, a monthly cell phone bill, or a box set of DVDs. In a month you could buy a digital camera or MP3 player.
• Ask the teen: “Do you feel that cigarettes control your life in any way?”

Secondhand smoke exposure is harmful, and clinicians should ask parents or guardians about their tobacco use and offer cessation advice and assistance during the child’s pediatric visit.\(^1,3,4,7,38\) (Grade B)
Other Tobacco and Nicotine Users
Smokeless tobacco users (i.e., chewing tobacco, snuff) or users of nicotine products (i.e., e-cigarettes) should be identified, strongly urged to quit and provided counseling cessation interventions.39-44 (Grade A)

Users of cigars, pipes, and other non-cigarette forms of smoking tobacco should be also be identified, urged to quit and provided counseling interventions. (Grade C) Provider should be aware that cigar smokers are at an increased risk for coronary heart disease, COPD, periodontitis and oral, esophageal, lung, and other cancers.45-48

The current evidence is insufficient to suggest that the use of pharmacotherapy increases long-term abstinence among users of smokeless tobacco.42,49,50

Hospitalized Tobacco Users
Hospitalized patients may be particularly motivated to make a quit attempt due to their potentially heightened perception of the health risks of smoking based upon the admitting illness, or due to their temporary housing in a smoke-free environment. The 2009 Wisconsin Act 12 Smoking Ban51 prohibits smoking within inpatient health care facilities, and The Joint Commission requires every accredited hospital to be smoke-free.1,5

During the admission intake, all patients should be asked about their tobacco use, advised to quit, and assessed regarding their willingness to make a quit attempt during the hospitalization (see above recommendations for additional details).1,5 (Grade A)

Patients who are willing to quit should undergo intensive behavioral intervention with supportive contact at least one month after discharge.25,52 (Grade A) Those patients unwilling to quit may have their withdrawal symptoms managed by nicotine-replacement therapy.1,5,14 (Grade A)

Pregnant Women
Due to the serious risks of smoking to the pregnant smoker and the developing fetus, pregnant smokers should be offered person-to-person psychosocial interventions that exceed minimal advice to quit1,53 (Grade A) For more intensive support, advise patients to contact the Quit Line (1-800-QUIT NOW), use Quit Line’s Fax to Quit (1-800-483-3114), or First Breath. Pharmacotherapy is not recommended for use in pregnant women.

Although abstinence from smoking produces the greatest benefit, quitting at any point during pregnancy is beneficial. Therefore, providers should identify and provide interventions during the first prenatal visit as well as throughout the course of pregnancy.1,4 (Grade B)
UW Health Implementation

Potential Benefits: Tobacco cessation and improved health.

Potential Harms: Nicotine dependent patients attempting to quit tobacco use may experience a range of unpleasant withdrawal symptoms, both physical and psychological. Use of pharmacologic therapy may reduce withdrawal symptoms, while introducing potential side effects of the medication.

Implementation Plan/Tools
1. Guideline will be housed on U-Connect in a dedicated space for Clinical Practice Guidelines.
2. Release of the guideline will be advertised in the Clinical Knowledge Management Corner within the Best Practice Newsletter.
3. Links to the guideline will be created within Health Link clinical tools, such as:

   SmartSets/Order Sets:
   - Tobacco Cessation [5088]
   - Passive Smoke Exposure [5326]
   - IP – Tobacco Abstinence – Adult – Supplemental [682]

   Reporting Workbench Reports:
   - IP Heart Failure Core Measure (HF-4) Adult smoking cessation counseling: admitted patients/ discharged patients
   - IP PN Core Measure (PN-4) Adult smoking cessation counseling: discharged patients
   - Audit- Smoking Cessation (24hrs/48hrs/72hrs/96hrs)

Disclaimer
CPGs are described to assist clinicians by providing a framework for the evaluation and treatment of patients. This Clinical Practice Guideline outlines the preferred approach for most patients. It is not intended to replace a clinician’s judgment or to establish a protocol for all patients. It is understood that some patients will not fit the clinical condition contemplated by a guideline and that a guideline will rarely establish the only appropriate approach to a problem.

References


Patient Presentation

Ask about Tobacco Use

Current User?

Pregnant?

Yes

Person-to-person psychosocial intervention

No

Advise to Quit

Repeat Motivational Intervention at every visit

Provide Motivational Intervention

Assess Willingness to Quit

Willing to Quit?

Yes

No

Assist via pharmacotherapy and counseling*

Complete Follow-up Contacts

Abstinence?

Yes

No

Reinforce tobacco-free lifestyle

Quit Recently?

Yes

No

Reinforce tobacco-free lifestyle

* Counseling may include brief intervention or intense counseling (referral) as well as education of quit lines, etc.
TOBACCO DEPENDENCE TREATMENT INPATIENT FLOWCHART

**Admissions**
Tobacco Use Screening
TOB-1

**Tobacco Use Treatment**
During Hospital Stay
TOB-2

**Tobacco Use Treatment**
At Discharge
TOB-3

**Follow-up**
Post-discharge
TOB-4

**ASK** about tobacco use in the 30 days prior to hospitalization and document in patient record

**Yes**

**ADVISE** all tobacco users to quit

**Yes interested in quitting**

**ASSESS** patient’s willingness to make a quit attempt during the hospitalization or interest in medications for symptom relief

**Not interested in quitting or medication for withdrawal symptoms**

**ASSESS** patient’s willingness to make a quit attempt during the hospitalization or interest in medications for symptom relief

**Interested in withdrawal symptom relief only**

**ASSIST**
- Provide practical counseling
- Provide medication
- Provide info on Quit Line
- Document in record

**ARRANGE**
- Refer patient to follow-up counseling and/or link to Quit Line via fax-to-quit
- Provide prescription for medication
- Document in record

**Contact patient within 30 days to determine tobacco use status or,**
- Use fax-to-quit outcome report to determine tobacco use status
- Document in record

**Contact patient within 30 days to determine tobacco use status**

**ARRANGE**
- Refer patient to follow-up counseling
- Provide prescription for medication
- Provide materials on Quit Line
- Document in record

**Contact patient within 30 days to determine tobacco use status**

**ASSIST**
- Provide info on Quit Line
- Document in record

**Contact patient within 30 days to determine tobacco use status**

**ARRANGE**
- Refer patient to follow-up counseling
- Provide prescription for medication
- Provide materials on Quit Line
- Document in record

**Contact patient within 30 days to determine tobacco use status**

**AFSSESS**
- Provide info on Quit Line
- Document in record

**Contact patient within 30 days to determine tobacco use status**

**ARRANGE**
- Refer patient to follow-up counseling
- Provide prescription for medication
- Provide materials on Quit Line
- Document in record

**Contact patient within 30 days to determine tobacco use status**

Last Reviewed: 08/2014
Contact CCKM for changes.
UW Health Tobacco Cessation - Pediatric/Adult - Inpatient/Ambulatory Guideline
Algorithm adopted from 2012 UW-CTRI